For example, Erlotinib is associated with the prolongation of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients with certain EGFR mutations, but with a shortening of PFS in patients with concurrent KRAS mutations [7]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.